The group of Xining SHAO at Xiamen University has used an E. coli expression system to express HEV capsid protein. Because the virus-like particle structure is highly similar to the native virus, with a large number of immunodominant epitopes, the human body, it stimulates the body to produce a large number of antibodies directed against hepatitis E virus. In 2004, The vaccine entered Phase III clinical testing in 2007. After completion in 2009, 120,000 volunteers were vaccinated in Jiangsu Province, confirming the vaccine’s effectiveness and safety.

China Bio news release, March 9, 2015